A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors by Spicer, J et al.
1 3
Cancer Chemother Pharmacol (2017) 79:17–27
DOI 10.1007/s00280-016-3189-1
ORIGINAL ARTICLE
A phase I study of afatinib combined with paclitaxel 
and bevacizumab in patients with advanced solid tumors
James Spicer1 · Sheeba Irshad1 · Joo Ern Ang2 · Deborah Enting1 · 
Rebecca Kristeleit2,3 · Martina Uttenreuther‑Fischer4 · Karine Pemberton5 · 
Katy Pelling5 · David Schnell4 · Johann de Bono2 
Received: 15 June 2016 / Accepted: 31 October 2016 / Published online: 21 November 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
bevacizumab 10 mg/kg. Frequent (any grade) treatment-
related adverse events (AEs) included diarrhea (83%), rash/
acne (83%), fatigue (79%), mucosal inflammation (59%), 
and nausea (59%). Based on overall safety, bevacizumab 
was amended to 7.5 mg/kg for the recommended phase 
II dose. Pharmacokinetic analyses suggested no relevant 
drug–drug interactions. Three (10%) confirmed partial 
responses were observed; 15 (52%) patients had stable 
disease.
Conclusions The recommended phase II dose schedule 
was afatinib 20 mg/day with paclitaxel 80 mg/m2 (Days 1, 
8, and 15 every 4 weeks) and bevacizumab 7.5 mg/kg every 
2 weeks. At this dose schedule, AEs were manageable, and 
anti-tumor activity was observed.
Keywords Afatinib · Paclitaxel · Bevacizumab · Phase I · 
Solid tumors
Introduction
Afatinib is an irreversible ErbB family blocker that selec-
tively and potently blocks signaling from all relevant ErbB 
family dimers (epidermal growth factor receptor [EGFR], 
human epidermal growth factor receptor 2 [HER2], ErbB4) 
and also inhibits transphosphorylation of ErbB3 [1]. 
Afatinib monotherapy has demonstrated substantial clinical 
activity in cancer types, including non-small cell lung can-
cer (NSCLC) and head and neck squamous cell carcinoma 
[2–6]. First-line afatinib significantly prolonged progres-
sion-free survival (PFS) versus platinum-based chemother-
apy in two phase III trials in patients with EGFR muta-
tion-positive NSCLC, and is approved for the treatment 
of these patients in several countries, including the USA 
and the European Union [4, 5]. Afatinib also improved 
Abstract 
Purpose The combination of afatinib, an irreversible 
ErbB family blocker, with paclitaxel and bevacizumab was 
assessed in patients with advanced solid tumors.
Methods This phase I study used a 3 + 3 design to deter-
mine the maximum tolerated dose (MTD) of afatinib com-
bined with paclitaxel and bevacizumab. Safety, pharma-
cokinetics, and anti-tumor activity were also assessed. The 
starting dose was oral afatinib 40 mg once daily plus intra-
venous paclitaxel (fixed dose 80 mg/m2, Days 1, 8, and 15 
of a 4-week cycle) and intravenous bevacizumab 5 mg/kg 
every 2 weeks.
Results Twenty-nine patients were enroled. The afatinib 
dose was de-escalated to 30 mg and then 20 mg after 2/6 
and 2/5 evaluable patients developed dose-limiting tox-
icities at 40 and 30 mg, respectively, when combined with 
paclitaxel and bevacizumab 5 mg/kg. The bevacizumab 
dose was subsequently escalated to 10 mg/kg, and MTD 
was defined as afatinib 20 mg plus paclitaxel 80 mg/m2 and 
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overall survival (OS) versus chemotherapy in patients with 
NSCLC harboring the EGFR Del19 mutation [6]. In more 
recent analyses, first-line afatinib significantly improved 
PFS, time-to-treatment failure, and objective response rate 
(ORR) versus gefitinib in patients with EGFR mutation-
positive NSCLC [7]. Additionally, afatinib demonstrated 
improved PFS and OS versus erlotinib, when given as sec-
ond-line therapy in patients with advanced squamous cell 
lung cancer following failure of platinum-based chemo-
therapy [8].
Chemotherapy remains a mainstay therapy option for 
many patients with advanced solid tumors. The combina-
tion of afatinib with tubulin-polymerizing agents, such 
as docetaxel or paclitaxel, was shown to be highly active 
in vitro and in vivo, indicating that the efficacy of these 
cytotoxic agents could be enhanced by blocking ErbB 
signaling [9]. The combination of afatinib and paclitaxel 
had a more than an additive effect on the inhibition of the 
proliferation of HER2-overexpressing SKOV-3 ovarian 
carcinoma cells, and had an additive effect in HT29 colon 
cancer cells in soft agar compared with single-agent treat-
ment. Based on this, a phase I dose-escalation trial (part of 
an overall larger study assessing different drug combina-
tions) to explore the efficacy and safety of afatinib in com-
bination with paclitaxel was conducted in 16 patients with 
advanced solid tumors [10]. The maximum tolerated dose 
(MTD) was established as afatinib 40 mg once daily com-
bined with paclitaxel 80 mg/m2 weekly. At this dose, the 
combination was tolerable, and adverse events (AEs) were 
generally manageable with repeated dosing; as expected, 
the most frequently observed AEs were rash, diarrhea, and 
fatigue. Promising anti-tumor activity was observed, with 
five (31%) patients achieving confirmed partial responses 
[PRs; this included patients with NSCLC (n = 3), esopha-
geal cancer (n = 1), and cholangiocarcinoma (n = 1)].
Bevacizumab is a recombinant humanized monoclonal 
antibody to vascular endothelial growth factor A (VEGF-
A) [11]. By preventing VEGF-A from binding to its recep-
tor, bevacizumab inhibits tumor angiogenesis, growth, and 
metastasis [12]. In Europe, bevacizumab is approved, in 
combination with other therapies, for the treatment of sev-
eral different types of cancer, including advanced colorec-
tal cancer, NSCLC, renal cell carcinoma, ovarian cancer, 
cervical cancer, and metastatic breast cancer [13]. There 
is excellent rationale and clinical precedent for combining 
paclitaxel with bevacizumab [14, 15]. Furthermore, given 
the broad use of bevacizumab across several tumor types, 
and as afatinib and bevacizumab have different mechanisms 
of action and can each be combined with chemotherapy, we 
assessed the combination of afatinib, paclitaxel, and beva-
cizumab in patients with solid tumors. We hypothesized 
that the combination could significantly potentiate the 
anti-tumor effects of each compound alone. This study was 
designed to determine the MTD of afatinib in combination 
with paclitaxel and bevacizumab in patients with advanced 
solid tumors in a phase I dose-escalation trial. The safety, 
pharmacokinetics, and preliminary anti-tumor efficacy of 
the combination were also evaluated.
Methods
Patients
Eligible patients were aged ≥18 years with advanced, 
recurrent or metastatic solid malignancies. Patients were 
also required to have adequate organ function, Eastern 
Cooperative Oncology Group performance status of 0 or 1, 
and life expectancy of at least 3 months. Exclusion crite-
ria included gastrointestinal dysfunction that could impair 
oral absorption; significant cardiovascular disease, use of 
full-dose anticoagulation medication; persistent grade ≥2 
(Common Terminology Criteria for Adverse Events 
[CTCAE] version 3.0) neurotoxicity or neuropathy; treat-
ment with chemotherapy, immunotherapy, radiotherapy, 
hormone therapy, EGFR- or HER2-targeting drugs or 
other investigational agents within 4 weeks prior to start of 
therapy; known preexisting interstitial lung disease; active 
infectious disease; untreated or symptomatic brain metasta-
ses; intra-abdominal inflammation or major surgery within 
4 weeks of treatment start. Patients with conditions con-
traindicating the use of bevacizumab (significant hyperten-
sion or hemoptysis, thrombotic or hemorrhagic disorders, 
international normalized ratio ≥1.5 or squamous NSCLC) 
were excluded.
Study design and treatment
This was a phase I, open-label, 3 + 3 design, dose-esca-
lation trial of afatinib combined with paclitaxel and beva-
cizumab. Patients received oral afatinib as a continuous 
once-daily dose beginning on Day 2 of Cycle 1 in combi-
nation with weekly paclitaxel administered intravenously 
(on Days 1, 8, and 15 of a 28-day cycle). Bevacizumab was 
administered on Days 1 and 15, after infusion of paclitaxel.
The starting dose in this part of the trial was based on 
the MTD previously established for afatinib plus pacli-
taxel (afatinib 40 mg/day and paclitaxel 80 mg/m2/week) 
[10]. Bevacizumab, given every 2 weeks, was added to the 
combination of afatinib and paclitaxel at a starting dose of 
5 mg/kg, with a planned escalation to 10 mg/kg in the sub-
sequent dose cohort (an intermediate dose of bevacizumab 
7.5 mg/kg could be explored if there were dose-limiting 
toxicities (DLTs) at the 10 mg/kg dose). In case of toxicity 
at the starting dose, a lower dose of afatinib and/or pacli-
taxel was planned.
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If a DLT occurred during the first or additional treat-
ment cycles, treatment was to be paused. Upon recovery of 
toxicities to baseline or CTCAE grade ≤1 (whichever was 
higher) within 14 days, treatment was permitted to resume 
at reduced doses. Treatment was administered in 28-day 
cycles; patients were eligible to receive up to 6 cycles of 
combination treatment in the absence of disease progres-
sion or intolerable toxicity. After 6 cycles of treatment, 
patients with clinical benefit (tumor response or absence 
of tumor progression) had the option to continue treatment 
with afatinib, with or without combination therapy, during 
an extension phase.
The primary endpoint was determination of the MTD of 
bevacizumab in combination with afatinib and paclitaxel. 
MTD was defined as the highest dose of afatinib, pacli-
taxel, and bevacizumab at which no more than one out of 
six patients experienced drug-related DLTs during Cycle 1. 
Secondary endpoints included evaluation of safety, phar-
macokinetics, and preliminary efficacy.
Safety assessments
AEs were assessed by CTCAE version 3.0 and inves-
tigators determined relationship to treatment. All AEs 
occurring between the first administration of study drug 
until 28 days after last administration of study drug 
were recorded as on-treatment AEs. DLTs were defined 
as any of the following treatment-related AEs occurring 
in the first 4 weeks of treatment: grade 4 uncomplicated 
neutropenia (fever ≤38.3 °C) for >7 days; neutropenia 
of any duration associated with fever >38.5 °C; plate-
lets <25,000/μl or grade 3 thrombocytopenia associ-
ated with bleeding requiring transfusion; grade ≥2 fall 
in cardiac left ventricular function; uncontrolled hyper-
tension despite multiple anti-hypertension therapies; 
grade ≥2 worsening of renal function; grade >2 diarrhea 
despite supportive treatment; persistent grade ≥2 diarrhea 
for ≥7 days despite supportive treatment; grade >2 nausea 
and/or vomiting despite anti-emetic treatment; persistent 
grade ≥2 vomiting for ≥7 days despite anti-emetic treat-
ment; all other drug-related non-hematological toxicities 
of grade ≥3 except incompletely treated nausea, vomiting 
or diarrhea.
Pharmacokinetic analysis
Blood was collected on Day 1 of Cycle 1 (for determination 
of paclitaxel and bevacizumab levels only) immediately 
before and after paclitaxel infusion, at 2.5, 6, and 24 h after 
the start of paclitaxel infusion and on Day 15 of Cycle 1 
(for determination of paclitaxel, bevacizumab, and afatinib) 
immediately before and after paclitaxel infusion, and then 
at 2, 2.5, 3, 4, 6, 8, and 24 h after the start of paclitaxel 
infusion. Additional pharmacokinetic samples were also 
collected on Day 15 of Cycle 4 and Day 1 of Cycle 5 (3 
samples each).
Afatinib and paclitaxel concentrations were determined 
by validated high-performance liquid chromatography tan-
dem mass spectrometry assays (HPLC–MS/MS); bevaci-
zumab drug concentrations were analyzed by a validated 
enzyme-linked immunosorbent assay. Non-compartmental 
analyses and descriptive statistics of afatinib and paclitaxel 
pharmacokinetic parameters were performed using Win-
Nonlin® version 5.2 and SAS® version 9.2. For the model-
based historical comparison of observed and expected 
bevacizumab plasma concentrations, the population phar-
macokinetic model by Lu et al. [16] was used as a math-
ematical representation of historical bevacizumab data. 
Expected bevacizumab concentrations were simulated 
based on the actual patient characteristics, dosing history, 
and sampling schedule as observed in the present study. 
Simulations and data processing were performed using 
NONMEM® version VI.2.0, and R version 2.12.1.
Efficacy assessments
Tumor imaging, using computed tomography, was per-
formed at screening and every 8 weeks after the start of 
treatment. Tumor response was evaluated by the investi-
gators according to Response Evaluation Criteria in Solid 
Tumors (RECIST version 1.0). Best overall response to 
treatment was defined as the best tumor response recorded 
at any time from the start of treatment to the earliest of 
disease progression, death or end of treatment. In patients 
with objective response (complete response [CR] or PR), 
this was confirmed by a repeat tumor assessment at least 
4 weeks later. In patients with stable disease (SD), the 
criteria of SD were to be met after a minimum interval of 
6 weeks of study participation.
Statistical analyses
The treated set, comprising all patients who received at 
least one dose of study medication, was used for analy-
ses of safety and efficacy. All statistical analyses were 
descriptive.
Results
Patients and treatment
A total of 29 patients were treated in the study at two cent-
ers in the UK. Patient demographics at baseline are shown 
in Table 1. The majority of patients had NSCLC (38%) or 
esophageal cancer (14%), and the patients were heavily 
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pretreated, with 97% having received previous chemother-
apy, 45% prior radiotherapy, and 7% each having received 
prior hormone therapy, immunotherapy, and biological 
therapy.
Twenty-three patients completed the first treatment 
cycle, and 11 (38%) completed 6 cycles of therapy. Overall 
mean time on treatment was 157.5 days (median 108; range 
13–629).
Maximum tolerated dose
Of 29 patients treated, 26 patients were evaluable for deter-
mination of MTD. Three patients were excluded due to 
discontinuation/interruption of study medication during 
the first 3 weeks of trial participation for reasons other than 
DLTs.
In Cohort 1 (afatinib 40 mg, paclitaxel 80 mg/m2, and 
bevacizumab 5 mg/kg), three patients were enroled and 
one was replaced due to non-evaluability for determi-
nation of MTD. A DLT was observed (grade 3 fatigue) 
and three additional patients were treated at this dose 
level. Another DLT (grade 3 fatigue and diarrhea) was 
observed. Cohort 2 therefore used a reduced dose of 
afatinib (afatinib 30 mg, paclitaxel 80 mg/m2 and beva-
cizumab 5 mg/kg).Three patients were treated with no 
DLT observed. Owing to the safety profile of the previ-
ous cohort, this cohort was expanded. The fourth and fifth 
patients entering the cohort experienced DLTs (grade 3 
paronychia and grade 3 diarrhea, respectively). In Cohort 
3, the afatinib dose was further reduced (afatinib 20 mg, 
paclitaxel 80 mg/m2, and bevacizumab 5 mg/kg). Three 
patients were treated, and none experienced DLTs. The 
bevacizumab dose was therefore increased in Cohort 4 
(afatinib 20 mg, paclitaxel 80 mg/m2, and bevacizumab 
7.5 mg/kg), and three patients were treated. One DLT 
(grade 3 mucositis) was observed in the third patient. An 
additional three patients were entered, and no further DLT 
was observed. In Cohort 5, the bevacizumab dose was fur-
ther increased (afatinib 20 mg, paclitaxel 80 mg/m2, and 
bevacizumab 10 mg/kg), and three patients were initially 
enroled in this cohort. A fourth patient was then treated 
(due to one patient being replaced) who experienced 
a DLT (grade 3 dysphonia); thus, an additional three 
patients were entered; one was not evaluable for determi-
nation of MTD and was replaced with a fourth patient. No 
further DLTs were observed.
Of the six patients with DLTs, three had DLTs leading 
to permanent discontinuation of trial medication. The MTD 
of the triplet combination was afatinib at 20 mg once daily 
continuously with paclitaxel at 80 mg/m2 (Days 1, 8, and 
15 every 4 weeks) and bevacizumab at 10 mg/kg every 
2 weeks.
Safety
Across all dose groups, treatment-related AEs were 
observed in 28 (97%) patients; the most frequent treat-
ment-related AEs (any grade) were diarrhea (83%), rash/
acne (83%), fatigue (79%), mucosal inflammation (59%), 
and nausea (59%; Table 2). The majority of AEs were mild 
to moderate in intensity: treatment-related grade 3 AEs 
occurred in 10 (34%) patients; the most common were diar-
rhea (n = 4; 14%) and fatigue (n = 3; 10%; Table 2). No 
grade 4 treatment-related AE or treatment-related death 
was observed.
Four patients sustained on-treatment AEs which led to 
death; none were considered to be related to study medi-
cation. One patient experienced lobar pneumonia and 
arrhythmia while on-treatment. Two patients had disease 
progression leading to death (17 and 15 days after last 
administration of trial medication). Another patient experi-
enced worsening dyspnea related to progressive lung can-
cer and despite discontinuation of trial medication.
Table 1  Patient demographics and tumor characteristics at baseline
a Other tumor types were as follows: bladder (n = 1), breast (n = 1), 
cancer of unknown primary (n = 1), pleura (n = 1), thyroid and para-
thyroid (n = 1)
b Including biological therapy
Characteristic Patients
N = 29
Age, years
Median (range) 58.0 (21–73)
Gender, n (%)
Male 12 (41)
Female 17 (59)
ECOG PS, n (%)
0 3 (10)
1 26 (90)
Tumor type, n (%)
NSCLC 11 (38)
Esophageal 4 (14)
Ovarian 3 (10)
Biliary tree 2 (7)
Cervical 2 (7)
Kidney 2 (7)
Othera 5 (17)
Previous therapies, n (%)
Chemotherapy 28 (97)
Surgery 14 (48)
Radiotherapy 13 (45)
Immunotherapy 2 (7)
Hormone therapy 2 (7)
Otherb 2 (7)
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Twelve (41%) patients experienced AEs leading to dis-
continuation of trial medication, three (10%) due to DLTs 
and nine (31%) due to other AEs. Serious AEs considered 
related to study medication occurred in nine patients (31%); 
the most frequent being diarrhea (five patients; 17%).
Based on the overall safety profile, the recommended 
phase II dose was defined as the combination of afatinib at 
20 mg/day with weekly paclitaxel at 80 mg/m2 and bevaci-
zumab every 2 weeks at 7.5 mg/kg (Cohort 4). At this dose, 
AEs were generally manageable. Grade 3 AEs consisted of 
diarrhea (n = 2), mucosal inflammation (n = 1), anemia 
(n = 1), and dehydration (n = 1; Table 2).
Pharmacokinetics
The pharmacokinetic profile of paclitaxel was evaluated 
in the presence of bevacizumab on Day 1 and in the pres-
ence of afatinib and bevacizumab on Day 15. Steady-state 
pharmacokinetics of afatinib was assessed in the pres-
ence of paclitaxel and bevacizumab (Day 15), and evalu-
ated in comparison with previously published data for 
afatinib monotherapy [17] (Table 3). Pharmacokinetic 
data suggested there were no relevant drug–drug interac-
tions between afatinib and paclitaxel (Table 3). Results 
from a model-based comparison with historical data [16] 
suggested that afatinib had no clinically relevant effect 
on the pharmacokinetics of bevacizumab (Supplementary 
Table 1).
Anti‑tumor activity
Of 29 treated patients, 10 patients were not evaluable for 
response. Confirmed PRs were observed in three patients: 
two patients with NSCLC and one patient with squamous 
cell carcinoma of the cervix (Fig. 1). As such, the ORR in 
the overall population (n = 29) was 10%. Confirmed SD 
was the best response in 15 (52%) patients; two of these 15 
patients had an unconfirmed PR (one patient with NSCLC 
and one patient with breast cancer). The disease control rate 
was therefore 62% (18/29 patients). Treatment duration and 
best confirmed response for individual patients is shown in 
Fig. 1. Best changes from baseline in tumor measurements 
for evaluable patients are shown in Fig. 2.
Of note, 11 of the 29 treated patients had NSCLC. 
Among these patients, the ORR was 18% (2/11; both con-
firmed PRs), and the disease control rate was 73% (8/11); 
three patients with NSCLC were not evaluable for response. 
Of the three patients in the study with treatment durations 
of >1 year, two had NSCLC and treatment durations of 529 
and 629 days (the additional patient experiencing treatment 
duration >1 year had cervical cancer). Figure 3 shows com-
puted tomography images for a patient with NSCLC who 
was treated in Cohort 2 (afatinib 30 mg, paclitaxel 80 mg/
m2 and bevacizumab 5 mg/kg). The patient had an uncon-
firmed PR and received afatinib for 629 days.
Discussion
Afatinib 20 mg/day in combination with bevacizumab 
every 2 weeks at 10 mg/kg and paclitaxel 80 mg/m2/week 
was established as the MTD in this phase I study, but is not 
recommended by investigators for long-term administration 
due to the incidence of non-DLT AEs. Therefore, the rec-
ommended dose for phase II studies was defined as afatinib 
20 mg/day with weekly paclitaxel 80 mg/m2 and 2-weekly 
bevacizumab 7.5 mg/kg. At the recommended phase II 
dose, the AEs of afatinib combined with paclitaxel and 
bevacizumab were generally mild to moderate and manage-
able; the most frequent treatment-related AEs at this dose 
were diarrhea, rash/acne, fatigue, nausea, alopecia, and 
epistaxis. Overall, this AE profile is consistent with that 
observed in the trial combining paclitaxel and afatinib [10]; 
however, AEs were generally more frequent and occurred 
at a higher grade with the triple combination compared 
with the doublet combination, resulting in a lower afatinib 
dose for the MTD. Bevacizumab and afatinib are both 
associated with fatigue and diarrhea, and these AEs were 
responsible for DLTs in three patients. However, no new 
AEs were identified with the triplet combination, compared 
with the doublet.
Bevacizumab was initially added to the MTD previously 
established for afatinib in combination with paclitaxel. 
However, as discussed earlier, at this dose, the triple com-
bination was not well tolerated and resulted in the afatinib 
dose being reduced to 20 mg. This raises an important con-
sideration of how best to add an agent, such as afatinib, to 
approved and established agents with established dosing 
regimens [18]. We designed the current trial to escalate the 
afatinib dose in combination with fixed doses of the estab-
lished drugs paclitaxel and bevacizumab. As such, when 
DLTs occurred, it was initially the afatinib dose which was 
22 Cancer Chemother Pharmacol (2017) 79:17–27
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reduced, while paclitaxel and bevacizumab doses were 
maintained where possible. As an alternative, the doses of 
paclitaxel and bevacizumab could also have been adapted, 
knowing that bevacizumab is used at a range of different 
doses in various regimens [11, 19, 20]. Whether this would 
have impacted the overall tolerability and efficacy profile 
of the triple combination is unclear, but should be consid-
ered for future trials evaluating novel combinations with 
established agents.
Pharmacokinetic analyses suggested no clinically rel-
evant drug–drug interactions between afatinib, paclitaxel, 
and bevacizumab. Pharmacokinetic parameters for afatinib 
at 40 mg daily within the triple combination were in line 
with those previously reported for afatinib monotherapy 
and for afatinib combined with paclitaxel [10, 21].
Anti-tumor activity was observed with this triplet com-
bination, with three confirmed PRs, resulting in an ORR of 
10%, and SD rate of 52%, in a heavily pretreated patient 
population. The triplet combination reported here builds 
on the two-drug combination of afatinib and paclitaxel, 
which we have previously reported to be well tolerated 
and clinically active in a phase I combination [10], and 
also in a phase III trial in NSCLC patients with acquired 
resistance to erlotinib or gefitinib who had progressed on 
afatinib after initial clinical benefit [22]. Overall, the addi-
tion of bevacizumab had a significant impact on the safety 
profile of afatinib/paclitaxel. This appears to be in line 
with other studies assessing the addition of bevacizumab 
to ErbB-targeted agents or chemotherapy. For example, 
a meta-analysis showed that while the addition of beva-
cizumab to chemotherapy or erlotinib improved efficacy 
outcomes in NSCLC, it was associated with a higher inci-
dence of grade ≥ 3 AEs [23]. However, first-line combina-
tion treatment with erlotinib and bevacizumab was shown 
to significantly improve PFS over erlotinib alone in patients 
with EGFR mutation-positive NSCLC [24], and such com-
binations of EGFR tyrosine kinase inhibitors with VEGF-
targeting antibodies are in clinical development for molec-
ularly defined subpopulations of lung cancer patients.
In conclusion, the MTD was defined as afatinib 20 mg/
day in combination with paclitaxel 80 mg/m2/week and 
bevacizumab 10 mg/kg every 2 weeks. However, as a 
result of tolerability, the recommended phase II dose was 
afatinib 20 mg/day in combination with paclitaxel 80 mg/
m2/week and bevacizumab 7.5 mg/kg every 2 weeks. 
Although the addition of bevacizumab was associated with 
Fig. 1  Dose modification scheme, DLTs, treatment duration, and 
best overall response in individual patients by dose cohorta. aOnly 
patients who were evaluable for DLT are displayed in this figure. The 
different shades of the time bars reflect allocation to different treat-
ment cohorts. bDLTs occurring during the first cycle of treatment are 
indicated for each patient, where relevant. CUP cancer of unknown 
primary, DLT dose-limiting toxicity, NE not evaluable
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a higher incidence of AEs compared with the combination 
of afatinib and paclitaxel, this triple combination demon-
strated anti-tumor activity, with documented objective 
responses and prolonged SD.
Acknowledgements This study was supported financially by 
Boehringer Ingelheim, as well as by the UK Department of Health 
via the National Institute for Health Research (NIHR) Biomedical 
Research Centre (BRC) award to Guy’s & St Thomas’ NHS Founda-
tion Trust in partnership with King’s College London and King’s Col-
lege Hospital NHS Foundation Trust (and NIHR Clinical Research 
Facility), and to The Institute of Cancer Research and Royal Mars-
den Hospital NHS Foundation Trust. King’s College London and the 
Royal Marsden hold Experimental Cancer Medicine Centre grants. 
The authors would like to acknowledge Matthias Friewald, from 
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany, 
for his work on the model-based analysis used to evaluate bevaci-
zumab pharmacokinetic parameters. Medical writing assistance, 
funded by Boehringer Ingelheim, was provided by Caroline Allinson 
of GeoMed, an Ashfield company.
Compliance with ethical standards 
Conflict of interest James Spicer reports consultant/advisory roles 
from Boehringer Ingelheim Ltd. Sheeba Irshad, Joo Ern Ang, Deborah 
Enting, and Rebecca Kristeleit have declared no conflict of interest. 
Martina Uttenreuther-Fischer, Karine Pemberton, Katy Pelling, and 
David Schnell report employment from Boehringer Ingelheim Ltd. 
Johann de Bono reports consultant/advisory roles from AstraZeneca, 
GlaxoSmithKline, Genentech, Astellas, and Sanofi.
Fig. 2  Waterfall plot for 
evaluable patients: best change 
from baseline in target lesions 
sum of diameters (%) and best 
confirmed overall response 
(RECIST version 1.0). aBest 
response was unconfirmed 
partial response, where sub-
sequent measurements were 
non-confirmatory. bThis patient 
had CR in the target lesion but 
progressive disease in nontarget 
lesions; best overall response of 
SD was observed at the previ-
ous assessment. CUP cancer of 
unknown primary
Cer
vix30
20
–10
b
Be
st
 c
ha
ng
e 
fr
om
 b
as
el
in
e 
(%
) i
n 
ta
rg
et
 le
si
on
s 
su
m
 o
f d
ia
m
et
er
s
–20
–30
–40
–50
Best confirmed overall responsea
Progressive disease
Partial response
Stable disease
Patients (n = 19)
–60
–70
–80
–90
–100
–110
10
0
Cer
vix
Kid
ney
Eso
pha
gus
Eso
pha
gus
Bili
ary
 tre
e
NSC
LC
NSC
LC
NSC
LC
NSC
LC
NSC
LC
NSC
LC
NSC
LC
NSC
LC
Bre
ast
Ova
ry
Ova
ry
CUPThy
roid
a
a
Fig. 3  Computed tomography images showing an unconfirmed par-
tial response in a patient with NSCLC who received afatinib 30 mg, 
paclitaxel 80 mg/m2, and bevacizumab 5 mg/kg. This patient received 
afatinib for 629 days. A partial response was reported twice in this 
patient during the study; however, these are considered to be uncon-
firmed partial responses because, at the consecutive tumor assess-
ments, the percentage change in tumor lesions did not meet RECIST 
v1.0 criteria for partial response
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